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Abstract
Background: Simultaneous colorectal and hepatic surgery for colorectal cancer (CRC) is increasing as
surgery becomes safer and less invasive. There is controversy regarding the morbidity associated with
simultaneous, compared with separate or staged, resections.
Methods: Data for 2005–2008 from the National Surgical Quality Improvement Program (NSQIP) were
used to compare morbidity after 19 925 colorectal procedures for CRC (CR group), 2295 hepatic
resections for metastatic CRC (HEP group), and 314 simultaneous colorectal and hepatic resections (SIM
group).
Results: An increasing number of simultaneous resections were performed per year. Fewer major
colorectal and liver resections were performed in the SIM than in the CR and HEP groups. Patients in the
SIM group had a longer operative time and postoperative length of stay compared with those in either the
CR or HEP groups. Simultaneous procedures resulted in higher rates of postoperative morbidity and
major morbidity than CR procedures, but not HEP procedures. This difference was driven by higher rates
of wound and organ space infections, and a greater incidence of septic shock. Mortality rates did not
differ among the groups.
Conclusions: Hospitals in the NSQIP are performing more simultaneous colonic and hepatic resections
for CRC. These procedures are associated with increases in operative time, length of stay and rate of
perioperative complications. Simultaneous procedures do not, however, increase perioperative mortality.
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Introduction
Colorectal cancer (CRC) is the fourth most frequently diagnosed
malignancy worldwide1,2 and is the second leading cause of
cancer-related death.1 One third of patients with CRC present
with stage IV disease with synchronous liver metastasis.3 Over the
last few decades there have been significant improvements in the
management of CRC with liver metastasis, resulting in the near-
doubling of 5-year survival from 30–35% in the 1980s and 1990s
to 50–65% in the current era.4,5 This improvement is related to
multiple factors, including advanced technical strategies which
have increased the feasibility and safety of resection of colorectal
liver metastases (CRLM),6 in combination with significant
improvements in systemic chemotherapy and targeted therapy.7
Complete resection of all liver metastases is a key factor in achiev-
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ing this result.8 Only 20% of patients with synchronous CRLM
have resectable disease at diagnosis.2 In line with a better under-
standing of the disease, the new trends shift management strate-
gies away from initial resection of the primary tumour (the classic
approach) towards protocols in which treatment of the liver
disease is the primary goal. Liver resection can be carried out prior
to or simultaneously with colorectal surgery9 (Fig. 1).
Simultaneous resection of CRLM along with the colorectal
primary tumour has multiple advantages. First, simultaneous
resection involves a single surgical procedure and general anaes-
thetic, which lower the overall hospital cost and length of stay
(LoS) compared with those of two separate procedures and hos-
pitalizations.10 In addition, removal of all neoplastic foci at once
may result in interruption of the metastatic cascade and avoid
tumour progression that may occur as a result of postoperative
immunosuppression associated with the staged approach.11
Finally, the simultaneous approach may avoid the occurrence
of delays and interruptions in chemotherapy administration.
The disadvantage of simultaneous resection is that there is a
potential increase in morbidity as a result of combining two
major abdominal procedures, one clean and the other clean-
contaminated.12 There have also been some concerns regarding
an increased risk for anastomotic leak as a result of splanchnic
congestion associated with pedicle clamping (Pringle manoeu-
vre) during liver resection, inadequate surgical exposure through
a single incision, and the difficulty of coordinating two separate
surgical teams.10
Over the last decade, multiple single-institution series have
consistently demonstrated the safety of simultaneous colorectal
resections and minor hepatic resections. Studies have shown
similar, and sometimes improved, rates of perioperative mortality
and morbidity, intraoperative blood loss, operative time and hos-
pital LoS in comparison with those associated with the classic
staged approach.13–16 By contrast, there is conflicting evidence
about the safety of performing colorectal procedures simultane-
ously with major liver resections: some reports have demonstrated
an acceptable safety profile14,17–20 and others have shown a signifi-
cant increase in perioperative mortality and morbidity compared
with the staged approach.21,22
With the exception of a multi-institution study by Reddy
et al.,21 most published reports constitute single-institution expe-
riences with small numbers of patients, which limits the ability to
make definitive conclusions regarding the feasibility and safety of
simultaneous resection. The American College of Surgeons’
National Surgical Quality Improvement Program (ACS NSQIP) is
an important surgical quality programme for general and vascular
surgery in the USA.23 Data are risk-adjusted and case mix-
adjusted. For each patient, over 136 pre-, intra- and postoperative
variables are prospectively collected by trained nursing staff for
30 days after surgery and data are audited annually for accuracy
and completeness.24 The ACS NSQIP has hundreds of participat-
ing hospitals and includes large numbers of patients, and thus its
database can provide an excellent opportunity to study the 30-day
outcomes of the simultaneous approach to resection of CRLM on
a national level. The aim of this study was to compare morbidity
and mortality in the simultaneous resection of primary CRC and
hepatic metastases with those in colorectal and hepatic resections,
respectively, using ACS NSQIP data.
Materials and methods
For this study, de-identified ACS NSQIP Participant Use File
(PUF) data for 2005–2008 were utilized. During the study period,
the ACS NSQIP collected detailed patient data for individuals
undergoing general surgical procedures in 211 participating uni-
versity and community hospitals. This study was approved by the
Penn State Hershey Medical Center Institutional Review Board.
The ACS NSQIP and the hospitals participating in the ACS
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Figure 1 Management of colorectal cancer with synchronous liver metastasis
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NSQIP represent the source of the data used herein; these insti-
tutions have not verified and are not responsible for the statistical
validity of the data analysis or the conclusions derived by the
present authors.
Patients and procedures
All patients who underwent colon and liver resection were iden-
tified by primary Current Procedural Terminology (CPT) codes
(Appendix 1). Postoperative diagnoses of CRC or secondary liver
cancer were identified using International Classification of Dis-
eases [Version 9 (ICD-9)] codes (Appendix 2). To identify patients
undergoing simultaneous colorectal and liver resection, secondary
CPT codes were reviewed, for which NSQIP has two categories:
‘other’ CPT codes, designed for additional procedures performed
by the same surgical team, and ‘concurrent’ CPT codes, designed
for additional procedures performed by a different surgical team.
A total of 22 534 patient records that met these definitions were
identified. These included records for 19 925 (88.4%) patients
who underwent colorectal procedures alone for primary colorec-
tal malignancy (CR cohort), 2295 (10.2%) patients submitted to
hepatic resections alone for colorectal neoplasms (HEP cohort),
and 314 (1.4%) patients who underwent simultaneous colorectal
and hepatic resections for primary colorectal malignancy (SIM
cohort). In order to compare surgical complexity, ‘major’ colorec-
tal resections were considered to include low anterior resec-
tion, total colectomy and total proctocolectomy. ‘Major’ hepatic
resections were considered to include hemi-hepatectomy and
trisegmentectomy.
Statistical analysis
Mean and median values were used to describe continuous data,
with discrete variables displayed as totals and frequencies. For
bivariate analyses, two-tailed t-tests and Mann–Whitney U-tests
were used to compare continuous data, whereas the Fisher exact
or chi-squared tests were used for categorical variables. A P-value
of <0.05 was considered to indicate statistical significance. All
statistical analyses were performed using spss Statistics Version
19.0.0 (IBM Corp., Armonk, NY, USA).
Outcomes definitions
Rates of 30-day mortality, minor and major morbidity, and hos-
pital LoS were examined. Minor morbidity included superficial
surgical site infections, urinary tract infections and deep vein
thrombosis or thrombophlebitis. Major morbidity followed the
definition outlined by Borja-Cacho et al.,25 and included deep
incisional surgical site infection, organ or organ space surgical site
infection, wound disruptions, pneumonia, need for re-intubation,
pulmonary embolism, progressive renal insufficiency, acute renal
failure, cerebrovascular accidents, coma, peripheral nerve injury,
cardiac arrest, myocardial infarction, graft or flap failure, sepsis,
septic shock, need for return to the operating room, and >48 h on
a ventilator. Mortality was defined as death from any cause at any
time from the date of the procedure to 30 days after the procedure.
Results
Demographics and preoperative characteristics
Demographics and preoperative comorbidities of the study popu-
lation can be found in Table 1.
Operative and perioperative data
The frequency of simultaneous colorectal and hepatic resections
increased over time. Overall, SIM group patients accounted for
12.0% of all hepatectomies in the 4-year sample. The proportion
of SIM cases, as a percentage of hepatectomies, increased from
8.4% in 2005 to 12.7% in 2008.
Colorectal surgery in SIM group patients was left-sided in 135
cases (43.0%), sigmoid or rectal in 45 cases (14.3%), right-sided
or transverse colonic in 94 cases (30.0%), and of an unspecified
colorectal primary in 40 cases (12.8%). Hepatic and colorectal
resections were performed by the same surgical team in 74.8%
(n = 235) of patients in the SIM group. The complexity of surgical
procedures performed in the CR, HEP and SIM groups is shown
in Table 2.
Postoperative outcomes
The overall 30-day mortality rate was 2.2%; there was no differ-
ence in this outcome among the three groups (Table 3). The
overall incidence of postoperative morbidity was 25.0%. The SIM
group had a significantly higher incidence of postoperative mor-
bidity compared with the HEP group (29.3% versus 20.3%; P <
0.001), but not compared with the CR group (29.3% versus
25.0%; P = 0.094). Major morbidity was also higher in the SIM
compared with the HEP group (20.4% versus 14.9%; P = 0.011),
but not compared with the CR group (20.4% versus 16.7%;
P = 0.103).
Within the SIM group, postoperative outcomes in patients
undergoing major versus minor colorectal procedures and major
versus minor hepatectomy procedures were compared. Rates of
complications for each combination of procedure types are shown
in Table 4. When outcomes in patients undergoing major and
minor hepatectomy procedures within the SIM group were com-
pared, no significant difference was noted in rates of morbidity
(26.7% versus 30.3%; P = 0.578), major morbidity (21.7% versus
20.1%; P = 0.784) or mortality (1.7% versus 1.6%; P = 0.959).
Discussion
Synchronous CRLM is found in 20–30% of patients with CRC at
the time of presentation.3 Although such presentation is a negative
prognostic indicator,26 it is not a contraindication for surgical
resection if the disease can be removed.27 The management of
resectable synchronous CRLM represents a challenge to the multi-
disciplinary team, especially in patients with an asymptomatic
small primary tumour. The simultaneous resection of liver metas-
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tasis along with the colorectal primary tumour is one option
available in synchronous CRLM and current data indicate the
increasing utilization of such an approach in ACS NSQIP hospi-
tals over the study period. This trend coincides with an increased
number of publications demonstrating the safety and feasibility of
this approach.15–17,19,22,28,29
The current study shows that patients in the SIM group had
longer operative times compared with those in the HEP and CR
groups. Previously published literature describes shorter operative
times in the simultaneous compared with the staged approach,13–16
but these studies combined the operative times for separate color-
ectal and hepatic procedures in the staged group. By contrast, the
current results are based on comparisons of the SIM group with
the CR and HEP groups separately. No comparison with out-
comes in the CR and HEP groups combined could be made in this
study because these groups represent different sets of patient pro-
cedures performed at different institutions and by different sur-
gical teams. This also explains why the SIM group was found to
have a longer postoperative hospital stay compared with the CR
and HEP groups, respectively.
By contrast with previously published studies that showed
similar or even lower rates of postoperative morbidity after simul-
taneous resection compared with staged resection,14,17–19,30 this
study found significantly higher rates of overall and major mor-
bidity in the SIM group compared with the HEP group, but not
with the CR group. However, as with operative times and for the
same reasons, data for the SIM group could not be compared with
outcomes in the CR and HEP groups combined.
The driver of the increased morbidity in the SIM group was
infectious or septic complications. This finding echoes data cited
in the existing literature.12,31 One theory attributes this to the
combination of a clean case, liver resection, with a clean-
Table 1 Population description and comorbidities in the study population (n = 22 534)
CR group HEP group SIM group CR versus SIM HEP versus SIM
(n = 19 925, 88.4%) (n = 2295, 10.2%) (n = 314, 1.4%) P-value P-value
Age, years, median (range) 68 (16–90) 61 (21–90) 62 (26–90) < 0.001 0.024
Female, n (%) 9 672 (48.5) 1 029 (44.8) 158 (50.3) 0.532 0.067
Body mass index, kg/m2, median (range) 26.9 (9.6–88.4) 27.2 (10.0–79.2) 26.3 (17.0–72.6) 0.074 0.004
Tobacco use, n (%) 2 983 (15.0) 273 (11.9) 57 (18.2) 0.117 0.002
Ascites, n (%) 295 (1.5) 11 (0.5) 6 (1.9) 0.532 0.003
Functions independently, n (%) 19 080 (95.8) 2 278 (99.3) 306 (97.5) 0.289 0.002
Chronic pulmonary disease, n (%) 1 158 (5.8) 56 (2.4) 16 (5.1) 0.590 0.007
Dyspnoea, n (%) 2 804 (14.1) 189 (8.2) 32 (10.2) 0.043 0.200
Percutaneous coronary intervention, n (%) 1 336 (6.7) 107 (4.7) 9 (2.9) 0.007 0.148
Cardiac surgery, n (%) 1 390 (7.0) 93 (4.1) 13 (4.1) 0.050 0.941
Hypertension, n (%) 10 918 (54.8) 1 059 (46.1) 151 (48.1) 0.018 0.517
Diabetes, n (%) 3 361 (16.7) 329 (14.3) 38 (12.1) 0.079 0.537
Heart failure, n (%) 259 (1.3) 4 (0.2) 2 (0.6) 0.302 0.108
Dialysis, n (%) 93 (0.5) 6 (0.3) 0 0.225 0.364
Weight loss, n (%) 1 328 (6.7) 91 (4.0) 38 (12.1) < 0.001 < 0.001
Chemotherapy, n (%) 514 (2.6) 304 (13.2) 24 (7.6) < 0.001 0.005
Radiation therapy, n (%) 1 962 (9.8) 37 (1.6) 43 (13.7) 0.024 < 0.001
ASA score of 3, n (%) 10 739 (53.9) 1 625 (70.8) 203 (64.6) < 0.001 0.025
CR, colorectal surgery only; HEP, hepatic surgery only; SIM, simultaneous hepatic and colorectal surgery; ASA, American Society of Anesthesiologists.
Table 2 Operative complexity and details in the study population (n = 22 534)
CR group HEP group SIM group CR versus SIM HEP versus SIM
(n = 19 925, 88.4%) (n = 2295, 10.2%) (n = 314, 1.4%) P-value P-value
Major colorectal resection, n (%) 5169 (25.9) – 68 (21.7) 0.932 –
Major hepatic resection, n (%) – 771 (33.6) 60 (19.1) – < 0.001
Operative time, min, median (range) 148.0 (6–1614) 216.0 (20–991) 265.5 (65–832) < 0.001 < 0.001
Blood transfusion, units, median (range) 0 (0–23) 0 (0–40) 0 (0–40) < 0.001 0.185
CR, colorectal surgery only; HEP, hepatic surgery only; SIM, simultaneous hepatic and colorectal surgery; Major colorectal resection: low anterior
resection, total colectomy and total proctocolectomy; Major hepatic resection: hemi-hepatectomy and trisegmentectomy.
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contaminated case, colorectal resection. Longer operative time is
also a risk factor for postoperative infection and may play a role in
its increased incidence. A study by de Santibanes et al. found that
simultaneous resection was associated with a high incidence of
overall postoperative morbidity (64%), particularly anastomotic
leak (21%).18 The authors identified longer operative time (> 8 h)
and increased intraoperative blood loss as independent risk
factors for septic complications.18 The increased postoperative
morbidity found in the SIM group did not translate to increased
mortality, a finding consistent with reports in the existing litera-
ture.15,16,32,33 In a review of outcomes in three large hepatobiliary
centres, Reddy et al.21 found that simultaneous colorectal and
major hepatic resections increased morbidity compared with
major hepatectomy alone. Others have shown that major hepate-
ctomy can be performed in a simultaneous fashion with no added
mortality or morbidity.17,34 This controversy may contribute to the
aversion of some surgeons to the performance of major resection
during simultaneous procedures. The current data demonstrate
that major hepatectomy was less common in the SIM group com-
pared with the HEP group. However, analysis of data for the SIM
group shows that there were no differences in morbidity or mor-
tality between those undergoing major and minor hepatectomy,
respectively. Neither did the combination of major colectomy and
major hepatectomy increase morbidity.
In 2009, Robertson et al.35 analysed survival after hepatic resec-
tion for CRLM using the National Cancer Institute’s Surveillance,
Epidemiology and End Results (SEER)–Medicare database. They
found the incidence of simultaneous resection (resection of colon
primary and liver metastases in the same hospitalization) to be
32%, which is higher than the 13.2% noted by the current study in
the ACS NSQIP database. Robertson et al. reported crude 30-day
and 90-day mortality rates after hepatic resection of 4.0% and
8.2%, respectively.35 In patients who underwent simultaneous
resection, the mortality rate was much higher (13.5%).35 Multi-
variate analysis showed simultaneous resection to be an independ-
ent factor for the increase in 90-day mortality.35 Although these
numbers are similar to those cited in a previously published
SEER–Medicare analysis,36 they are higher than the present find-
ings in the ACS NSQIP database (30-day mortality rates: 1.0% in
the HEP group, 1.6% in the SIM group), which are consistent with
the mortality rates of 0–3% reported in the literature.7,37,38
The current study has several limitations, most of which arise
from the nature of the NSQIP dataset. This study was able to
analyse only 30-day outcomes after colorectal, hepatic and simul-
taneous resections; this is an inherent limitation of the ACS
NSQIP database. Recently, there has been increasing evidence that
90-day postoperative follow-up gives a more accurate indication
of outcomes after hepatic resection.39 The majority of previously
Table 3 Postoperative morbidity in the study population (n = 22 534)
CR group HEP group SIM group CR versus SIM HEP versus SIM
(n = 19 925, 88.4%) (n = 2295, 10.2%) (n = 314, 1.4%) P-value P-value
Mortality, n (%) 471 (2.4) 23 (1.0) 5 (1.6) 0.371 0.341
Morbidity, n (%) 5075 (25.5) 466 (20.3) 93 (29.3) 0.094 < 0.001
Major morbidity, n (%) 3367 (16.9) 341 (14.9) 64 (20.4) 0.103 0.011
LoS, days, median (range) 6 (1–187) 5 (1–138) 7 (1–108) < 0.001 < 0.001
Superficial SSI, n (%) 1713 (8.6) 92 (4.0) 30 (9.6) 0.549 < 0.001
Deep SSI, n (%) 313 (1.6) 13 (0.6) 10 (3.2) 0.024 < 0.001
Organ SSI, n (%) 682 (3.4) 107 (4.7) 23 (7.3) < 0.001 0.042
Dehiscence, n (%) 322 (1.6) 15 (0.7) 8 (2.5) 0.196 0.001
Sepsis, n (%) 552 (2.8) 58 (2.5) 17 (5.4) 0.005 0.004
Reoperation, n (%) 1243 (6.2) 80 (3.5) 18 (5.7) 0.713 0.050
Pneumonia, n (%) 620 (3.1) 70 (3.1) 10 (3.2) 0.941 0.897
Re-intubation, n (%) 531 (2.7) 61 (2.7) 10 (3.2) 0.571 0.591
Pulmonary embolism, n (%) 162 (0.8) 28 (1.2) 5 (1.6) 0.130 0.580
CR, colorectal surgery only; HEP, hepatic surgery only; SIM, simultaneous hepatic and colorectal surgery; LoS, length of stay; SSI, surgical site
infection.
Table 4 Morbidity by complexity of surgery at simultaneous resection in 314 patients
Minor CR and minor HEP Major CR and minor HEP Minor CR and major HEP Major CR and major HEP
(n = 203, 64.6%) (n = 51, 16.2%) (n = 43, 13.7%) (n = 17, 5.4%)
Mortality, n (%) 4 (1.3%) 0 1 (0.3%) 0
Morbidity, n (%) 60 (19.1%) 17 (5.4%) 12 (3.8%) 4 (1.3%)
Major morbidity, n (%) 37 (11.8%) 14 (4.5%) 10 (3.2%) 3 (1.0%)
CR, colorectal surgery; HEP, hepatic surgery.
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published articles on the subject looked primarily at the short-
term postoperative outcomes of simultaneous resection to prove
its feasibility and safety. Less evidence is available on the longterm
oncologic outcomes, but recently published articles have analysed
both short- and longterm outcomes and found similar rates of 3-
and 5-year survival in simultaneous resection and the staged
approach.18,40 This dataset also lacks preoperative laboratory
values for many patients.41 Although this is more common in
healthier patients undergoing low-risk procedures, the lack of
data is not random. As a result of this limitation, preoperative
laboratory values were not included in the analysis.
Conclusions
The current study is one of the first to evaluate the outcomes of
simultaneous resection of CRLM in a population-based database.
This study notes an increase in the proportion of simultaneous
procedures performed over the years of the study period at ACS
NSQIP hospitals. Although simultaneous resection did not
increase 30-day mortality, it was associated with increases in
operative time, postoperative LoS and rate of septic complications
compared with separate colorectal surgery and hepatectomy.
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Appendix 1 Current Procedural Terminology
(CPT) codes
Colorectal procedure codes
44140–44147 Partial removal of the colon
44150 Removal of the colon
44151–44156 Removal of the colon with ileostomy
44157 Colectomy with ileoanal anastomosis
44158 Colectomy with neo rectum pouch
44160 Removal of the colon
44204 Laparoscopic partial colectomy
44205 Laparoscopic partial colectomy with ileum
44206 Laparoscopic partial colectomy with stoma
44207 Colectomy with coloproctostomy
44208 Colectomy with coloproctostomy
45110 Partial removal of the rectum
45111 Partial removal of the rectum
44210 Laparoscopic total proctocolectomy
44211 Laparoscopic colectomy with proctectomy
44212 Laparoscopic total proctocolectomy
45160 Excision of rectal lesion
45170 Excision of rectal lesion
45395 Laparoscopic removal of the rectum
45397 Laparoscopic removal of the rectum with pouch
45112 Removal of the rectum
45113 Partial proctectomy
45114 Partial removal of the rectum
45116 Partial removal of the rectum
45119 Removal of the rectum with reservoir
45120 Removal of the rectum with reservoir
45121 Removal of the rectum and colon
45123 Partial proctectomy
45550 Repair of the rectum and removal of sigmoid
Hepatectomy procedure codes
47120 Partial removal of the liver
47122 Extensive removal of the liver – trisegmentectomy
47125 Partial removal of the liver – left lobectomy
47130 Partial removal of the liver – right lobectomy
47370 Laparoscopic ablation of liver lesion –
radiofrequency
47371 Laparoscopic ablation of the liver – cryoablation
47379 Laparoscopic liver procedure
47380 Open ablation of the liver – radiofrequency
47381 Open ablation of liver tumour – cryoablation
74399 Liver surgery procedure
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Appendix 2 International Classification of
Diseases (ICD-9) codes
153 Malignant neoplasm of the colon
153.1 Malignant neoplasm of the transverse colon
153.2 Malignant neoplasm of the descending colon
153.3 Malignant neoplasm of the sigmoid colon
153.4 Malignant neoplasm of the cecum
153.6 Malignant neoplasm of the ascending colon
153.7 Malignant neoplasm splenic flexure
153.8 Malignant neoplasm other sites in the colon
153.9 Malignant neoplasm unspecified site in the colon
154 Malignant neoplasm at the rectosigmoid junction
154.1 Malignant neoplasm of the rectum
154.8 Malignant neoplasm other sites rectosigmoid junction
197.5 Secondary malignant neoplasm of large intestine and rectum
197.7 Malignant neoplasm of liver, secondary
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